Browse by category

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of ischaemic optic neuropathy (ION) and sudden sight loss of the semaglutide drugs, according to a study by researchers from the University of Ottawa, Ottawa, Ontario, Canada. They found that the risk is almost five times higher with Wegovy than it is with Ozempic, and three times greater in men than it is in women. ION is caused by inadequate/interrupted blood flow to the optic nerve, resulting in sudden vis